BG
KRYS icon

Bellevue Group’s Krystal Biotech KRYS Stock Holding History

Bellevue Group’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28.8M Sell
77,530
-404,255
-84% -$121M 0.61% 40
2026
Q1 		$124M Buy
481,785
+71,462
+17% +$19M 2.96% 10
2025
Q4 		$101M Buy
410,323
+409,011
+31,175% +$86.1M 1.92% 16
2025
Q3 		$232K Buy
1,312
+62
+5% +$9.28K ﹤0.01% 132
2025
Q2 		$172K Sell
1,250
-1,400
-53% -$206K ﹤0.01% 129
2025
Q1 		$478K Sell
2,650
-2,397
-47% -$403K 0.01% 117
2024
Q4 		$791K Buy
5,047
+268
+6% +$47.5K 0.02% 122
2024
Q3 		$870K Buy
4,779
+581
+14% +$112K 0.01% 122
2024
Q2 		$771K Sell
4,198
-612
-13% -$103K 0.01% 123
2024
Q1 		$856K Sell
4,810
-3,190
-40% -$443K 0.01% 124
2023
Q4 		$992K Sell
8,000
-4,500
-36% -$499K 0.02% 122
2023
Q3 		$1.45M Sell
12,500
-5,500
-31% -$671K 0.02% 117
2023
Q2 		$2.11M Sell
18,000
-300
-2% -$30.6K 0.03% 113
2023
Q1 		$1.47M Hold
18,300
– – 0.02% 121
2022
Q4 		$1.45M Hold
18,300
– – 0.02% 129
2022
Q3 		$1.28M Buy
18,300
+4,900
+37% +$354K 0.02% 131
2022
Q2 		$880K Sell
13,400
-400
-3% -$24.9K 0.01% 138
2022
Q1 		$918K Sell
13,800
-200
-1% -$12.5K 0.01% 151
2021
Q4 		$979K Buy
+14,000
New +$815K 0.01% 156

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Bellevue Group's KRYS Position: Q2 2026 in Review

Bellevue Group reduced its Krystal Biotech (KRYS) stake by 84% in Q2 2026, selling an estimated $121M and leaving 77,530 shares worth $28.8M. The position accounts for 0.61% of the portfolio, ranked #40.

Bellevue Group first reported a position in KRYS in Q4 2021 and has held it in 19 quarters since. The position peaked at $124M in Q1 2026. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Bellevue Group held 77,530 shares of Krystal Biotech worth $28.8M as of Q2 2026.
  • Bellevue Group sold 404,255 Krystal Biotech shares in Q2 2026, an estimated $121M.
  • Krystal Biotech made up 0.61% of Bellevue Group's portfolio in Q2 2026, its #40 holding.
  • Bellevue Group first reported a position in Krystal Biotech in Q4 2021 and has held it in 19 quarters since.
  • Bellevue Group's Krystal Biotech position peaked at $124M in Q1 2026.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Bellevue Group's 13F filing for Q2 2026, filed 14 Aug 2026.